Published in Antimicrob Agents Chemother on April 01, 1999
High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium. J Clin Microbiol (2006) 1.17
In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.08
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains. Antimicrob Agents Chemother (2001) 1.00
First characterization of fluoroquinolone resistance in Streptococcus suis. Antimicrob Agents Chemother (2006) 0.98
In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Antimicrob Agents Chemother (2003) 0.95
In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique. Antimicrob Agents Chemother (2001) 0.92
Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria. Antimicrob Agents Chemother (2011) 0.89
High abundance and diversity of antimicrobial resistance determinants among early vancomycin-resistant Enterococcus faecium in Poland. Eur J Clin Microbiol Infect Dis (2013) 0.88
Dogs leaving the ICU carry a very large multi-drug resistant enterococcal population with capacity for biofilm formation and horizontal gene transfer. PLoS One (2011) 0.87
Comparison of mismatch amplification mutation assay with DNA sequencing for characterization of fluoroquinolone resistance in Neisseria gonorrhoeae. J Clin Microbiol (2004) 0.81
A multicentre hospital outbreak in Sweden caused by introduction of a vanB2 transposon into a stably maintained pRUM-plasmid in an Enterococcus faecium ST192 clone. PLoS One (2014) 0.81
Drug-resistant and hospital-associated Enterococcus faecium from wastewater, riverine estuary and anthropogenically impacted marine catchment basin. BMC Microbiol (2014) 0.81
Draft Genome Sequence of Enterococcus faecalis Strain F165 Isolated from a Urinary Tract Infection. Genome Announc (2016) 0.75
Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 40.37
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol (1994) 7.89
Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol (1990) 7.61
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother (1996) 7.10
Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother (1993) 5.96
Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob Agents Chemother (1989) 5.80
Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1995) 5.64
ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother (1996) 4.78
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 4.42
4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother (1991) 4.35
Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1993) 4.27
Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother (1996) 4.15
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother (1996) 3.95
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother (1997) 3.83
Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother (1993) 2.68
Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother (1993) 2.48
Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1994) 2.43
Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 2.17
Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist (1998) 1.80
Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob Agents Chemother (1993) 1.65
Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother (1995) 1.44
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1998) 1.40
An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) (1995) 1.38
Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones. Antimicrob Agents Chemother (1995) 1.31
A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics. Antimicrob Agents Chemother (1997) 1.19
Amino acid variation in the GyrA subunit of bacteria potentially associated with natural resistance to fluoroquinolone antibiotics. Antimicrob Agents Chemother (1997) 1.06
Mechanism of quinolone uptake into bacterial cells. J Antimicrob Chemother (1991) 0.99
Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin. Diagn Microbiol Infect Dis (1996) 0.96
Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates. Diagn Microbiol Infect Dis (1995) 0.94
Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium. Antimicrob Agents Chemother (1996) 0.81
Protease-deficient mutants of Pseudomonas aeruginosa: pleiotropic changes in activity of other extracellular enzymes. J Gen Microbiol (1977) 2.59
Assessment of protease (elastase) as a Pseudomonas aeruginosa virulence factor in experimental mouse burn infection. Infect Immun (1979) 2.48
Purification and properties of a protease with elastase activity from Pseudomonas aeruginosa. J Gen Microbiol (1977) 2.41
Evaluation of two test-kits--API and Oxi Ferm tube--for identification of oxidative-fermentative Gram-negative rods. Med Microbiol Immunol (1977) 2.31
Enterotoxin, haemolysin and cytotoxic protein in Aeromonas hydrophila from human infections. Acta Pathol Microbiol Scand B (1976) 2.22
Pseudomonas aeruginosa elastase and its role in pseudomonas infections. Rev Infect Dis (1984) 2.14
Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother (2000) 2.07
Persistence of local cytokine production in shigellosis in acute and convalescent stages. Infect Immun (1995) 1.88
Mutations in the hemolytic-phospholipase C operon result in decreased virulence of Pseudomonas aeruginosa PAO1 grown under phosphate-limiting conditions. Infect Immun (1989) 1.87
Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist (1998) 1.80
Genetic mapping and characterization of Pseudomonas aeruginosa mutants defective in the formation of extracellular proteins. J Bacteriol (1984) 1.77
Rothmund-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndrome. Am J Med Genet (2000) 1.72
Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma. J Infect Dis (1995) 1.64
Comparison of Western blot and enzyme-linked immunosorbent assay for diagnosis of Lyme borreliosis. Eur J Clin Microbiol Infect Dis (1989) 1.58
Separation of two hemolysins from Aeromonas hydrophila by isoelectric focusing. Infect Immun (1971) 1.57
Relation between antibody response to Pseudomonas aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis. Acta Paediatr Scand (1984) 1.54
Production of enzymes and toxins by hospital strains of Pseudomonas aeruginosa in relation to serotype and phage-typing pattern. J Med Microbiol (1973) 1.51
Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis (1995) 1.51
Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol (1987) 1.49
Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. J Antimicrob Chemother (1988) 1.48
Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infect Immun (1999) 1.48
Formation of extracellular haemolysin by Aeromonas hydrophila in relation to protease and staphylolytic enzyme. J Gen Microbiol (1973) 1.45
Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis (1995) 1.39
Separation and characterization of enterotoxin and two haemolysins from Aeromonas hydrophila. Acta Pathol Microbiol Scand B (1981) 1.38
Dialysis culture enables more accurate determination of MIC of benzylpenicillin for Borrelia burgdorferi than does conventional procedure. Antimicrob Agents Chemother (1996) 1.38
Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia. Antimicrob Agents Chemother (1974) 1.35
Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. Hum Genet (1997) 1.33
Protein secretion in Pseudomonas aeruginosa: molecular cloning and characterization of the xcp-1 gene. J Bacteriol (1989) 1.32
Evaluation of serologic assays for diagnosis of whooping cough. J Clin Microbiol (1988) 1.32
Comparison of flagellum and sonicate antigens for serological diagnosis of Lyme borreliosis. Eur J Clin Microbiol Infect Dis (1990) 1.28
Diagnostic value of clinical and bacteriological findings in pertussis. J Infect (1991) 1.26
Molecular detection and identification of Candida and Aspergillus spp. from clinical samples using real-time PCR. Clin Microbiol Infect (2006) 1.24
Tissue, cell type, and breast cancer stage-specific expression of a TGF-beta inducible early transcription factor gene. J Cell Biochem (1998) 1.23
Characterization of three Aeromonas and nine pseudomonas species by extracellular enzymes and haemolysins. Med Microbiol Immunol (1975) 1.22
Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC. Antimicrob Agents Chemother (1998) 1.22
Identification of medically important fungi by the Pyrosequencing technology. Mycoses (2004) 1.18
Cloning of xcp genes located at the 55 min region of the chromosome and involved in protein secretion in Pseudomonas aeruginosa. Mol Microbiol (1989) 1.16
Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother (1992) 1.15
Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa. Clin Microbiol Infect (2004) 1.12
Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia. Eur J Pediatr (1996) 1.10
Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids. Infect Immun (1981) 1.08
Sensitivity of interleukin-6 and C-reactive protein concentrations in the diagnosis of acute appendicitis. Eur J Surg (1995) 1.07
Interleukin-6 and interleukin-8 in serum and urine in patients with acute pyelonephritis in relation to bacterial-virulence-associated traits and renal function. Nephron (1994) 1.05
Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother (1996) 1.04
Mechanisms of resistance to imipenem in imipenem-resistant, ampicillin-sensitive Enterococcus faecium. APMIS (2001) 1.04
Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect (2008) 1.02
The mucociliary activity of the respiratory tract. I. Inhibitory effects of products of Pseudomonas aeruginosa on rabbit trachea in vitro. Acta Otolaryngol (1981) 1.01
Down-regulation of gamma interferon, tumor necrosis factor type I, interleukin 1 (IL-1) type I, IL-3, IL-4, and transforming growth factor beta type I receptors at the local site during the acute phase of Shigella infection. Infect Immun (1995) 1.01
Antibiotic sensitivity of two Aeromonas and nine Pseudomonas species. Med Microbiol Immunol (1975) 1.01
Age at acquisition of Helicobacter pylori infection: comparison of a high and a low prevalence country. Scand J Infect Dis (1996) 1.00
Comparison of two methods of genetic exchange in determination of the genetic locus of the structural gene for Pseudomonas aeruginosa elastase. J Bacteriol (1983) 0.99
Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia. Eur J Clin Microbiol Infect Dis (1993) 0.99
Occurrence of P-fimbriated Escherichia coli in patients with bacteremia. Eur J Clin Microbiol (1985) 0.98
Experimental infections with protease-deficient mutants of Pseudomonas aeruginosa in mice. J Med Microbiol (1978) 0.98
Dissociation between cytokine mRNA expression and protein production in shigellosis. Eur J Immunol (1996) 0.98
The role of proteases and exotoxin A in the pathogenicity of Pseudomonas aeruginosa infections. Scand J Infect Dis Suppl (1981) 0.98
Haemophilus influenzae and Streptococcus pneumoniae induce different intracerebral mRNA cytokine patterns during the course of experimental bacterial meningitis. Clin Exp Immunol (1997) 0.97
Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis. Infect Immun (1995) 0.97
The use of biochemical markers, serotype and fimbriation in the detection of Escherichia coli clones. J Gen Microbiol (1987) 0.97
Polymorphisms in cytokine genes influence long-term survival differently in elderly male and female patients. J Intern Med (2007) 0.94
Meropenem susceptibility breakpoint for Pseudomonas aeruginosa strains hyperproducing mexB mRNA. Clin Microbiol Infect (2005) 0.92
Characterization of a Pseudomonas aeruginosa transposon insertion mutant with defective release of exoenzymes. J Gen Microbiol (1987) 0.92
Cytokine gene expression during experimental Escherichia coli pyelonephritis in mice. J Urol (1997) 0.91
Assessment of elastase as a Pseudomonas aeruginosa virulence factor in experimental lung infection in mink. Vet Microbiol (1987) 0.91
Will triclosan in toothpaste select for resistant oral streptococci? Clin Microbiol Infect (2003) 0.89
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-1 receptor antagonist in dialysate and serum from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis (1996) 0.89
Bacteriology of maxillary sinusitis in relation to quality of the retained secretion. Acta Otolaryngol (1978) 0.89
Cytokine mRNA profiles during the course of experimental Haemophilus influenzae bacterial meningitis. Clin Immunol Immunopathol (1997) 0.88
Plasmid analysis as an epidemiological tool in neurosurgical infections with coagulase-negative staphylococci. Epidemiol Infect (1987) 0.88
Interleukin-6 and interleukin-8 in the urine of children with acute pyelonephritis. Pediatr Nephrol (1994) 0.87
Predicting and preventing sudden death from cardiac causes. Circulation (1994) 0.87
Enzyme-linked immunosorbent assay for detection of antibodies to Pseudomonas aeruginosa exoproteins. Eur J Clin Microbiol (1985) 0.86
TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand J Infect Dis (2000) 0.86
Antibiotic concentrations in maxillary sinus secretions and in the sinus mucosa. Chemotherapy (1975) 0.86
Aerobactin-mediated uptake of iron by strains of Escherichia coli causing acute pyelonephritis and bacteraemia. J Infect (1988) 0.86
Changes in the peripheral blood T-Cell receptor V beta repertoire in vivo and in vitro during shigellosis. Infect Immun (1996) 0.86
Constrictive pericarditis presenting as recurrent ascites for 10 years. Saudi Med J (2007) 0.86
Enhanced generation of interleukins 1 beta and 6 may contribute to the cachexia of chronic disease. Am J Clin Nutr (1997) 0.86
Urine interleukin-6 and interleukin-8 in children with acute pyelonephritis, in relation to DMSA scintigraphy in the acute phase and at 1-year follow-up. Pediatr Radiol (1994) 0.85
Semiquantitative estimation of Shigella antigen-specific antibodies: correlation with disease severity during shigellosis. APMIS (1996) 0.84
Genetic mapping of the structural gene for phospholipase C of Pseudomonas aeruginosa PAO. J Bacteriol (1990) 0.83
Rapid identification of mutations in a multidrug efflux pump in Pseudomonas aeruginosa. APMIS (1999) 0.83
Catheter ablation for the treatment of paroxysmal supraventricular tachycardia. J Cardiovasc Electrophysiol (1995) 0.82
Antibody responses to Escherichia coli J5 lipopolysaccharide and to Salmonella porin in patients with bacteremia. Microb Pathog (1986) 0.82
Use of the antimicrobial removal device prior to blood culture in patients on antibiotic therapy. Eur J Clin Microbiol (1985) 0.82
Characterization of Escherichia coli isolated in blood, urine and faeces from bacteraemic patients and possible spread of infection. APMIS (1991) 0.82
Escherichia coli populations from diabetic and non-diabetic patients with bacteraemia and faecal samples from healthy subjects--a comparative study. Epidemiol Infect (1990) 0.82
Interleukin-1 alpha and interleukin-1 receptor antagonist in the urine of children with acute pyelonephritis and relation to renal scarring. Acta Paediatr (1996) 0.82
Differential expression of enteric neuroimmune-network in invasive and acute watery diarrhoea. Neurogastroenterol Motil (2009) 0.81
Interleukin-6 and interleukin-8 in dialysate and serum from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis (1993) 0.81
Enzyme-linked immunosorbent assay to evaluate the immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. J Clin Microbiol (1988) 0.81
Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.81
Plasmapheresis in the treatment of primary septic shock in humans. Scand J Infect Dis (1993) 0.81
Pseudomonas cepacia septicemia in patients with burns: report of two cases. Scand J Infect Dis (1985) 0.80
Uniparental disomy in congenital disorders: a prospective study. Am J Med Genet (1995) 0.79
Viridans streptococcal septicaemia in neutropenic patients: role of proinflammatory cytokines. Bone Marrow Transplant (2004) 0.79
IL-6 and IL-1 receptor antagonist in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction. J Intern Med (2000) 0.79
Listeriosis during pregnancy and in neonates. Scand J Infect Dis Suppl (1990) 0.78